基于颅外因素预测脑转移患者总生存的预后评分的外部验证
该研究对单中心524例接受颅内放疗的脑转移患者进行回顾性分析,外部验证基于血清白蛋白、乳酸脱氢酶和颅外转移器官数的EC-S评分,并与RPA、DS-GPA比较。EC-S的区分度最佳(CPE=0.626±0.022),校准也更好,能识别预后极差患者。EC-S与DS-GPA联合的新评分区分度略提高(CPE=0.636±0.023),但需更大队列进一步验证。
要点
- EC-S评分区分度最佳,CPE=0.626±0.022,优于RPA和DS-GPA。
- 低白蛋白、LDH升高且>1个颅外器官转移者中位生存仅0.6个月(CI95% 0.1-1.1)。
- EC-S与DS-GPA联合的新评分区分度略提高(CPE=0.636±0.023),需进一步验证。
核心结论
- 本研究独立验证了EC-S评分,该评分是界定从颅内放疗中总生存明显无获益患者的最佳预后模型。
- EC-S与已建立的DS-GPA评分联合使区分能力略有提高,新EC-GPA评分需在更大患者队列中进一步验证。
研究设计与样本
- 单中心524例接受颅内放疗的脑转移患者的回顾性分析。
- 计算并评估RPA(524例)、DS-GPA(464例)和Nieder等开发的EC-S(157例)的区分能力,EC-S基于血清白蛋白、LDH和颅外受累器官数。
- 区分度用Gönen & Heller一致性概率估计(CPE)评估,校准通过比较各风险组中位生存与源数据集对应值检查。
- 采用LASSO构建多变量Cox回归模型,纳入包括三个评分在内的大量变量。
主要发现
- EC-S的区分度最佳,CPE=0.626±0.022。
- EC-S校准更好,且区分预后极差患者的能力最佳:低白蛋白、LDH升高且>1个颅外器官转移者中位生存仅0.6个月(CI95% 0.1-1.1),与无颅外转移且白蛋白和LDH正常者相比死亡风险比HR=6.36(2.67-15.14)。
- 多变量Cox模型中保留的预后因素包括血清白蛋白、LDH、治疗方式、DS-GPA和EC-S。
- DS-GPA与EC-S临时组合的新评分可用于134例患者,区分度略优于DS-GPA或EC-S单独(CPE=0.636±0.023)。
关键数值与推荐
- EC-S评分基于血清白蛋白、LDH和颅外受累器官数。
- EC-S的CPE=0.626±0.022。
- 低白蛋白、LDH升高且>1个颅外器官转移者中位生存0.6个月(CI95% 0.1-1.1),HR=6.36(2.67-15.14)。
- EC-GPA新评分CPE=0.636±0.023,可用于134例患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 新EC-GPA评分需在更大患者队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of our study was an external validation of the extracranial prognostic score predicting survival of patients with brain metastases receiving cranial irradiation on data from a single institution. MATERIALS AND METHODS: A retrospective analysis of 524 patients with brain metastases treated with cranial radiotherapy in a single tertiary center was performed. Three predictive scores were calculated and assessed for their ability to discriminate prognostic groups: (i) The Recursive Partitioning Analysis (RPA) score (available for 524 patients); (ii) the Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) score (464 patients); (iii) the extracranial score (EC-S) developed by Nieder et al. which is based on serum albumin, lactate dehydrogenase (LDH) and the number of extracranial organs involved (157 patients). Discrimination of each score was assessed by Gönen & Heller's concordance probability estimate (CPE). The calibration was checked by comparing median survival estimates of each risk group with the corresponding values of the datasets from which the scores were derived. Finally, a multivariable Cox regression model was built by using the least absolute shrinkage and selection operator on a large number of variables including all three scores. RESULTS: With a CPE = 0.626 ± 0.022, the EC-S had the best discriminatory power. The EC-S also appeared to be better calibrated and had the best ability to separate patients with a very poor prognosis: patients with combination of low albumin, elevated LDH and more than 1 extracranial organ with metastatic involvement had a median survival time of only 0.6 months (CI95% 0.1-1.1) and a hazard ratio for death of 6.36 (2.67-15.14) compared to patients with no extracranial metastases and normal levels of albumin and LDH. In the multivariable Cox model serum albumin, LDH, treatment modality, DS-GPA and EC-S were retained as prognostic factors. An ad hoc combination of both DS-GPA and EC-S into a new score was possible for 134 patients and indicated a slightly better discrimination (CPE = 0.636 ± 0.023) than either DS-GPA or EC-S alone. CONCLUSIONS: This study provides an independent validation of the prognostic EC-S which was the best prognostic model for defining the patients who obviously did not benefit from radiation therapy of brain metastases in terms of overall survival. The combination of the EC-S with the established DS-GPA score resulted in a slight increase in discriminatory ability. The new EC-GPA score needs further validation in larger patient cohorts.
引用
- Lewitzki V, Klement RJ, Hess S, et al. External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors. Clin Transl Radiat Oncol. 2019. PMID: 30906886. doi:10.1016/j.ctro.2019.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。